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Carotid reconstruction was first performed 45
years ago for symptomatic carotid stenosis.1,2 Since
then, several multicenter trials have demonstrated
the beneficial effects of carotid endarterectomy
(CEA) for patients who are both symptomatic3,4 and
asymptomatic5,6 with carotid stenosis. Several stud-
ies, including seven reviewed in a consensus state-
ment, have shown that the risk of stroke increases
and is proportional to the degree of carotid artery
stenosis in patients with more than 70% diameter
reduction.7-9 It is therefore appropriate that patients
with severe (more than 80% diameter reduction)
asymptomatic carotid stenosis should be considered
for CEA.9,10 On the other hand, the treatment of
patients who are asymptomatic with lesser degrees of
stenosis had not been clearly defined when this study
was initiated.11-13 In 1992, we adopted a policy of
recommending CEA to patients who were asympto-
matic with severe (>80%) carotid stenosis. Because
of the uncertainty surrounding the proper treatment
of patients who are asymptomatic with 50% to 79%
stenosis, we chose to study this group closely in our
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Purpose: The incidence rate of disease progression and stroke after the diagnosis of a
moderate (50% to 79%) carotid stenosis was determined by means of color-flow duplex
scanning. 
Methods: During a 4-year period, 344 male veterans with moderate internal carotid
artery stenoses, on one or both sides, were examined at regular intervals for a mean peri-
od of 25 months. Carotid color-flow scans were obtained semiannually. Clinical follow-
up was performed to determine the incidence rate of amaurosis fugax, transient ischemic
attacks, nonhemispheric symptoms, and strokes.
Results: New neurologic symptoms developed in 75 patients (21.8%). Fifty-one (14.8%)
had ipsilateral symptoms during follow-up: 18 amaurosis fugax (5.2%), 14 transient
ischemic attacks (4%), 5 nonhemispheric symptoms (1.4%), and 14 strokes (4%). Twenty-
four patients (6.9%) had contralateral symptoms: 20 strokes (5.8%) and 4 transient
ischemic attacks (1.2%). Life-table analysis showed that the annual rate of ipsilateral neu-
rologic events was 8.1%, and the annual rate of stroke was 2.1%. Seventy-five patients
(22%) died in the follow-up period. Disease progression to 80% to 99% stenosis or occlu-
sion occurred in 71 of 458 vessels (15.5%). The internal carotid arteries that showed evi-
dence of disease progression had a significantly higher initial peak systolic velocity (251
vs 190 cm/s; P < .0001) and end diastolic velocity (74 vs 52 cm/s; P < 0.0001). Black
patients and patients with ischemic heart disease were at a higher risk for disease pro-
gression. We could not identify any atherosclerotic risk factors that reliably predicted
patients in whom future ipsilateral neurologic symptoms were more likely to develop.
However, there was an increased risk of stroke associated with progression of disease.
Conclusion: Patients who are asymptomatic and who have moderate carotid stenoses are
at significant risk for neurologic symptoms and death, but have a relatively low incidence
rate of ipsilateral events. The initial flow characteristics in the stenotic vessel are predic-
tive of future disease progression, but they are not helpful in identifying patients in
whom symptoms will develop. (J Vasc Surg 1999;29:217-27.)
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vascular laboratory with semiannual carotid duplex
scans (CFS). The neurologic outcome of our
patients who were asymptomatic with moderate
carotid artery stenosis (50% to 79%) was reviewed to
determine whether certain atherosclerotic risk fac-
tors or color-flow duplex scan criteria were success-
ful means of predicting disease progression. 
PATIENTS AND METHODS
Patient selection. During a 4-year period start-
ing in November 1992, 526 veterans with moderate
carotid stenosis were identified in the noninvasive vas-
cular laboratory at the Hines Veterans Administration
Hospital in Hines, Ill. We selected a subgroup of
patients who were asymptomatic at the time of pre-
sentation and who had a 50% to 79% diameter reduc-
tion in the internal carotid artery (ICA) on one or
both sides demonstrated by means of at least two con-
secutive color-flow duplex scans. Patients with recur-
rent carotid stenosis were excluded.
Follow-up. Patients were initially referred to the
vascular laboratory by internists or surgeons for inves-
tigation of asymptomatic carotid bruits or were being
screened before undergoing major thoracic, abdomi-
nal, or vascular operations. Once enrolled in the cere-
brovascular registry, patients were prospectively
placed on a routine 6-month schedule of carotid
duplex scanning. Demographic data were obtained
from a patient questionnaire that was filled out at the
initial visit and all subsequent visits. Additional infor-
mation regarding the onset of cerebrovascular events,
concomitant medical problems, medications, and risk
factors for atherosclerosis were derived from hospital
inpatient and outpatient charts and patient interviews.
Patients were considered to be symptomatic if they
reported symptoms of amaurosis fugax (AF), transient
ischemic attacks (TIAs), vertebrobasilar or ill-defined
neurologic (nonhemispheric NH) symptoms, or
strokes. The documentation of a new stroke was
obtained by means of computed tomography scans,
magnetic resonance imaging of the brain, a neurolog-
ic examination finding a permanent deficit, or a neu-
rologic examination lasting more than 24 hours.
Patients who missed their routine appointments were
contacted by means of telephone and registered mail
to reschedule the examinations. For patients who
died, the dates and causes of death were obtained
from the medical records or autopsy reports.
Color-flow duplex scanning. Cerebrovascular
studies were performed with an ATL Ultramark 9
high definition imaging (HDI, Advanced Technology
Laboratories, Bothell, Wash) by two experienced vas-
cular technologists, one of whom is certified. All
studies were reviewed by the vascular surgery attend-
ing physicians. Criteria for detecting moderate
carotid stenosis (50% to 79% diameter reduction of
the ICA) in our laboratory are based on identifying
a peak systolic velocity (PSV) of 125 cm/s in the
ICA. To identify a severe (80% to 99% diameter
reduction) ICA stenosis, we used an end diastolic
velocity (EDV) of 140 cm/s. Complete occlusion
was determined to be present if no flow was demon-
strated in the ICA. These criteria have been verified
and tested by means of an ongoing quality assurance
program to document accuracy. For 167 vessels
examined in a 3-year period with both color-flow
scanning and arteriography, the sensitivity, specifici-
ty, positive predictive values, and negative predictive
values were 99%, 96.8%, 98.1%, and 98.4%, respec-
tively. The overall accuracy was 98.2%. These data
are being submitted for accreditation by the
Intersocietal Commission for the Accreditation of
Vascular Laboratories.
Statistical analysis. Differences among patients
who had disease progression and those who did not
were examined with the Fisher exact test for categoric
variables; differences in continuous variables between
two and three groups were compared with the
Student t test and analysis of variance, respectively.
Variables associated with disease progression or mor-
tality on univariate analysis (P < .10) were entered
into a stepwise logistic regression model to identify
independent predictors of increasing carotid stenosis,
symptom development, or mortality. A two-sided P
value of .05 was considered statistically significant.
Life-table analysis was used to determine the cumula-
tive survival rate and neurologic outcomes of patients. 
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Fig 1. Atherosclerotic risk factors in patients with moder-
ate carotid stenosis.
HTN, Hypertension; ASA/Tic, aspirin, ticlopidine;
Hyperlip, hyperlipidemia; PVD, peripheral vascular disease;
CAD, coronary artery disease.
RESULTS
Patient characteristics. Our patients were vet-
erans receiving most of their care at our Veterans
Administration hospital. There were 344 men who
qualified for the study. The average age at presenta-
tion was 70.6 ± 7.2 years (range, 43 to 89 years).
Risk factors are depicted in Fig 1. The average num-
ber of follow-up color-flow duplex scans during the
study was 2.69 ± 0.63 per patient (range, 1 to 11
scans), and the average follow-up period with scans
was 24.9 ± 12.9 months (range, 2 to 61 months).
All records were updated in April 1998. We exclud-
ed 4 female patients and 74 patients who had a sin-
gle CFS but no follow-up study.
Neurologic events. In the follow-up period,
symptoms developed in 75 patients (21.8%). Fifty-
one patients had ipsilateral symptoms: 18 patients
(5.2%) had AF, 14 (4%) had TIAs, 5 (1.4%) had
nonhemispheric symptoms, and 14 (4%) had
strokes. The incidence rate of ipsilateral neurologic
events by means of life-table analysis was 6.4% at 1
year and 24.3% at 3 years (Table I; Fig 2). The 1-
year and 3-year stroke rates were 2.2% and 6.5%,
respectively (Table II; Fig 3). 
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Fig 2. Cumulative number of patients with asymptomatic moderate carotid stenosis who
remain ipsilateral neurologic event-free, including transient ischemic attacks, amaurosis fugax,
and stroke. The bars represent standard errors.
Table I. Ipsilateral neurologic event-free rate
Nonstroke deaths
Number Number + number surviving Number lost
Interval at risk of events incomplete interval to follow-up Interval (%) Cumulative (%) SE (%)
1 month 344 1 0 0 99.7 99.7 0.2
3 months 343 5 1 2 98.5 98.2 0.7
6 months 335 4 26 2 98.7 97.0 0.9
9 months 303 3 9 0 99.0 96.1 1.1
12 months 291 7 37 1 97.4 93.6 1.4
18 months 246 15 56 0 93.1 87.1 2.0
2 years 175 13 82 0 90.3 78.7 2.8
3 years 80 2 56 0 96.1 75.7 4.2
4 years 22 1 18 0 92.3 69.9 8.2
5 years 3 0 3 0 100 69.9 22.1
Contralateral symptoms, TIAs in four patients
and strokes in 20 patients, developed during the fol-
low-up period. There were 12 contralateral strokes
associated with ICA occlusion, one with 80% to 99%
stenosis, one post-CEA, and six with less than 80%
stenosis (Table III). 
Mortality. Seventy-five patients (21.8%) died in
the follow-up period; 11 deaths were related to
stroke. Thirty-six patients (48%) died of cardiac
causes, 15 (20%) of malignant disease, 7 (9%) of sep-
sis or pneumonia, and 12 (16%) of other causes. The
cause of death was unknown in 5 patients (7%).
One-year, 2-year, and 3-year survival rates were
91.8%, 73.3%, and 57.7%, respectively, by means of
life-table analysis (Table IV; Fig 4).
Disease progression. Overall, 458 vessels (in
344 patients) with 50% to 79% stenosis were used
for analysis. Disease progression from the moderate
stenosis (50% to 79%) category to a more severe
stenosis (80% to 99% or complete occlusion) was
identified in 71 vessels (15.5%) in 69 patients. Two
patients had bilateral disease progression. There
were six patients with moderate stenosis that pro-
gressed to total occlusion (Table V). The mean time
to progression was 15.8 ± 10.2 months (median, 12
months). Excluded from analysis were four other
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Fig 3. Cumulative number of patients with moderate asymptomatic moderate carotid steno-
sis who remain free from ipsilateral strokes. The bars represent standard errors.
Table II. Ipsilateral stroke-free rate
Nonstroke deaths
Number Number + number surviving Number lost
Interval at risk of stroke(s) incomplete interval to follow-up Interval (%) Cumulative (%) SE (%)
1 month 344 0 1 0 100 100 0.0
3 months 343 3 3 2 99.1 99.1 0.5
6 months 335 1 29 2 99.7 98.8 0.6
9 months 303 2 10 0 99.3 98.2 0.8
12 months 291 1 41 1 99.6 97.8 0.9
18 months 248 3 68 0 98.6 96.4 1.2
2 years 177 4 91 0 97.0 93.5 1.8
3 years 82 0 59 0 100 93.5 2.6
4 years 23 0 20 0 100 93.5 5.0
5 years 3 0 3 0 100 93.5 13.8
patients who showed disease progression on the side
opposite a 50% to 79% stenosis: one who had pro-
gression from less than 50% to 80% to 99%, one who
had a progression from less than 50% to 100%, and
two who had progressions from 80% to 99% to
100%. CEA was performed in 44 of 63 patients
(70%) in whom either symptomatic or asymptomatic
severe carotid stenosis developed; however, 19
patients refused to have an operation.
Duplex findings. The velocities measured on
the initial CFS were highly predictive of disease pro-
gression. Patients with progression had a significant-
ly higher PSV (251 cm/s vs 190 cm/s; P < .0001)
and EDV (74 cm/s vs 52 cm/s; P < .0001) in the
affected vessel on their first study.
Other baseline risk factors and clinical features
associated with an increased rate of progression were
race (black vs other; P < .001) and the presence of
coronary artery disease (P = .08). Age, sex, hyperten-
sion, diabetes mellitus, hyperlipidemia, peripheral vas-
cular disease, presence of abdominal aortic aneurysm,
tobacco and alcohol use, previous coronary artery
bypass, cancer, and the use of platelet antiaggregants
(aspirin and ticlopidine), antihypertensives, lipid-
lowering agents, digoxin, or insulin had no associa-
tion with carotid disease progression. After adjusting
for race and the presence of coronary artery disease,
initial end diastolic velocity was shown to be a signif-
icant independent predictor for subsequent disease
progression by means of multivariate analysis.
We arbitrarily selected the more-than-60%-stenosis
cutoff point to determine whether patients with that
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Fig 4. Cumulative number of surviving patients with moderate asymptomatic carotid steno-
sis. The bars represent standard errors.
Table III. Correlation between the initial carotid artery stenosis by duplex and subsequent onset of stroke
(458 vessels with moderate [50% to 79%] stenosis in 344 patients)
Ipsilateral 50% to 79% ICA stenosis
Contralateral <50% ICA stenosis 50% to 79% ICA stenosis 80% to 99% ICA stenosis ICA occlusion Total
Number of patients 153 114 30 47 344
Ipsilateral CVA 11 3 – – 14
Contralateral CVA 6 – 2* 12 20
*One patient had a contralateral CVA after carotid endarterectomy
ICA, internal carotid artery; CVA, stroke.
degree of stenosis were at a higher risk for neurolog-
ic symptoms. A PSV of 260 cm/s and EDV of 70
cm/s were previously shown to correlate best with a
60% stenosis.14 Using these criteria, we found no sig-
nificant differences between the PSV and EDV of
patients that had strokes compared with those who
did not (P = .40 and .54, respectively; Table VI).
Symptoms and disease progression. Overall,
18 of 69 patients (26%) with disease progression had
symptoms associated with the worsening stenosis,
compared with 33 of 275 patients (12%) with stable
disease (P = .01). Ten patients had disease progres-
sion demonstrated by means of CFS before the
onset of any neurologic symptoms. Eight patients
had symptoms before disease progression was docu-
mented: five had AF, one had a TIA, and two had
strokes. Seven of the 14 ipsilateral strokes that
occurred in our patients were associated with disease
progression (Table V). The incidence rate of stroke
was significantly higher in patients with increasing
stenosis (7 of 69), compared with those with stable
disease (7 of 275; P = .01). Three of six patients who
progressed to complete occlusion suffered strokes.
DISCUSSION
CEA is one of the most frequently performed vas-
cular operations in the United States.15 The North
American Symptomatic Carotid Endarterectomy Trial
(NASCET) and European Carotid Surgery Trial
(ECST) have both demonstrated that CEA is superi-
or to medical therapy alone in the treatment of symp-
tomatic patients with more than 70% stenosis.3,4
Conversely, in a later publication, the ECST showed
the lack of benefit from CEA in patients who were
symptomatic with 30% to 69% stenosis.16 The as-yet-
unpublished results from NASCET on patients who
were symptomatic with 30% to 69% stenosis have
recently been presented.17 The incidence rate of
stroke was 2.2% in the surgical arm, compared with
9.7% for patients in the medical arm of the study. For
patients who are in the 50%-to-69%-stenosis category,
the 5-year incidence rate of stroke was 15.7% in the
surgical group, compared with 22.2% in the medical
group. The relative risk reduction achieved by 
CEA was 29% (P = .045). The results from the
Veterans Administration asymptomatic trial and the
Asymptomatic Carotid Atherosclerosis Study (ACAS)
demonstrated that CEA is better than medical thera-
py in patients with moderate carotid stenosis.5,6 It
should be emphasized that the methods of measuring
carotid stenosis were different in the ECST, compared
with the NASCET and ACAS. An estimated 70%
stenosis by means of duplex and the ECST method is
equivalent to a 50% stenosis by means of the
NASCET and ACAS method.16,18,19
In a recent contemporary series of CEA in 2228
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Table IV. Survival rates
Number Number Number surviving Number lost
Interval at risk of deaths incomplete interval to follow-up Interval (%) Cumulative (%) SE (%)
1 month 344 0 1 0 100 100 0.0
3 months 343 1 2 2 99.7 99.7 0.3
6 months 338 6 23 2 98.2 97.9 0.8
9 months 307 6 6 0 98.0 95.9 1.1
12 months 295 12 31 1 95.7 91.8 1.5
18 months 251 10 62 0 95.1 87.6 1.9
2 years 179 23 71 0 84.0 73.6 2.8
3 years 85 13 48 0 78.7 58.0 4.1
4 years 24 3 18 0 80.0 46.3 6.9
5 years 3 1 2 0 50.0 23.2 11.7
Table V. Disease progression and symptom development
Number Mean time Progression before Symptoms before
Category of vessels (months) symptoms progression Asymptomatic
50% to 79% through 80% to 99% 65 16 9* (4) 6† 50
50% to 79% through 100% 6 12 1 (1) 2 (2) 3
Total 71 10 8 53
*2 amaurosis fugax and 3 transient ischemic attacks. 
†5 amaurosis fugax and 1 transient ischemic attack.
Patients who had strokes are in italics and parenthesis.
consecutive patients from the Cleveland Clinic,
excellent outcomes were reported. More than 60%
of patients who had CEAs in that series had asymp-
tomatic carotid stenoses.20 Nevertheless, there is an
apparent lack of consensus among clinicians on the
most appropriate treatment for patients with moder-
ate asymptomatic 50% to 79% carotid stenosis.11-13
One of the most frequently cited arguments against
CEA in this population is that the risk of stroke in
patients who are untreated is very low, on average
2% per year, and that the excellent surgical results
reported by the ACAS may be difficult to duplicate
in other, smaller centers. 
In this study, we reviewed the outcome of 344
asymptomatic male veterans, each of whom had at
least two carotid color-flow scans. During the aver-
age follow-up period of 2 years, 75 patients had new
neurologic events and ipsilateral symptoms devel-
oped in 51 patients. By means of life-table analysis,
the annual rate of ipsilateral neurologic events was
8.1%. Fourteen patients had ipsilateral strokes, for an
annual stroke incidence rate of 2.1%. These rates are
quite similar to those reported in other natural his-
tory studies (Table VII).21-23 Seventy-five patients
(22%) died during the follow-up period. Similar
mortality rates were reported by other investigators
who studied veterans with carotid stenosis.24
Concomitant medical conditions and atherosclerotic
risk factors were typical for this elderly male popula-
tion (Fig 1).
Serial color-flow duplex scans detected a rate of
progression from the moderate category to a more
severe stenosis in 15.5% of the vessels. There were
six vessels (1.2%) that progressed to complete occlu-
sion. Recently, Rockman et al23 reported on the out-
come of a similar group of patients and noted a rate
of progression to severe stenosis in 15.6% and to
total occlusion in 1.4%. Other carefully performed
studies reported similar rates (Table VII).21-23
Since the publication of the NASCET and the
ACAS, many laboratories have evaluated new crite-
ria to report a more than 60% and more than 70%
stenosis in their patients. Those investigators have
noted that it is more difficult to subdivide the 50%
to 79% moderate-stenosis category into deciles.25-27
Nevertheless, a PSV of 260 cm/s and EDV of 70
cm/s correlated best with a 60% stenosis on angiog-
raphy, measured by means of the ACAS criteria.27
Although we have not specifically tested those crite-
ria, in this study, the vessels that progressed to a
higher stenosis had initial velocities approaching the
60% mark. The velocities measured on the initial
carotid scans were highly predictive of disease pro-
gression.
It is tempting to assume that in patients who
have asymptomatic 50% to 79% carotid stenoses,
vessels that fall toward the upper end of this range
would be more likely to produce symptoms. This
concept was proven in the NASCET, in which
patients with the most severe stenosis (90% to 99%)
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Table VI. Prediction of disease progression using the 60% stenosis cutoff point
Velocity Sensitivity Specificity PPV NPV
PSV 260 cm/s 56% 80% 34% 91%
EDV 70 cm/s 43% 86% 37% 89%
PSV/EDV 260/70 36% 89% 38% 88%
PPV, Positive predictive value; NPV, negative predictive value; PSV, peak systolic velocity; EDV, end diastolic velocity.
Table VII. The natural history of moderate carotid stenosis in the literature
Author, year Patients (N) Follow-up (months) TIA Stroke Progression
Roederer, 1984 167 36 6 (3.6%) 4 (2.4%) 60%
Norris, 1990 696 41 75 (11%) 29 (4.2%) NR
Ellis, 1992 1198 20 33 (2.8%) 27 (2.3%) 3.1%
Shanik, 1992 188 48 6 (3.2%) 10 (5.3%) 28.6%
Bock, 1993 242 27 20 (8.3%) 15 (6.2%) NR
Mansour, 1995 142 44 7 (4.9%) 7 (4.9%) 16.9%
Johnson, 1995 232 84 NR 12 (5.2%) 23%
Nehler, 1996 263 20 NR NR 4%
Rockman, 1997 425 38 25 (5.9%) 16 (3.8%) 17%
Current, 1999 344 25 14 (4%) 14 (4%) 15.2%
TIA, Transient ischemic attack; NR, not reported.
received the most benefit from CEA in stroke reduc-
tion (26%). This benefit decreased to 12% for
patients with 70% to 79% stenosis.4 The ECST per-
formed a similar analysis on a group of patients who
were asymptomatic with stenosis proven by means of
angiography.8 The 3-year stroke risk was 9.8% for
patients with 80% to 89% stenosis and 14.4% for
those with 90% to 99% stenosis. No significant dif-
ferences were observed in the 3-year stroke risk of
patients with mild (1% to 29%) and those with mod-
erate stenosis (30% to 69%; 1.8% vs 2.1%). Similarly,
there were no apparent differences between the
50%-to-59%, 60%-to-69%, and 70%-to-79% groups.
The contribution of atherosclerotic risk factors to
disease progression and provocation of symptoms has
been studied. In the NASCET and other studies, the
number of risk factors appeared to correlate with
stroke incidence rates.4,22 Multivariate analysis in this
group of patients showed that, in addition to the ini-
tial velocity, race (blacks vs other) and the presence of
coronary artery disease correlated with patients who
had disease progression. We also noted that patients
with disease progression were at a significantly high-
er risk of sustaining ipsilateral symptoms (18 of 69 vs
33 of 275) and strokes (7 of 69 vs 7 of 275; both: P
= .01). In a recent study, considerable geographic
and racial variations in stroke incidence rates were
noted.28 Chambers and Norris7 noted that patients
with asymptomatic stenosis were more likely to die of
ischemic heart disease than stroke. In a more recent
report, Kronmal et al29 found that the rate of
ischemic stroke was significantly higher in patients
with cardiovascular disease (P < .0001).
A patient with an asymptomatic stenosis on one
side is at risk for a contralateral stroke. In our
patients, 20 strokes (59%) occurred opposite the
arteries with moderate stenosis, and 12 of those
were associated with an occluded ICA. We could not
identify any flow characteristics that could be used as
a means of predicting the future development of
neurologic events. Most of the strokes occurred in
this series without any premonitory symptoms. With
close surveillance, in theory, four strokes could have
been prevented by offering CEA at the time of
asymptomatic disease progression (Table V). This
number might have been higher, because prophylac-
tic CEA was performed in 34 patients. 
Most patients who progressed (44 of 63; 70%)
had a CEA after disease progression; however, sever-
al patients (19 of 63) declined to have an operation.
At the time of CEA, in addition to the 34 patients
who had remained asymptomatic, four patients had
episodes of AF, 3 had TIAs, and 3 had mild strokes.
The patients who had CEA had a higher incidence
rate of coronary artery disease (68% vs 46%; P =
.001) and hypertension (77% vs 63%; P = .03).
The objective of performing CEAs in patients
who are asymptomatic is stroke prevention. Clearly,
better patient selection is needed to identify those
who are at risk of developing symptoms. Several inves-
tigators have focused their efforts on carotid plaque to
find features that might predict the onset of neuro-
logic events. Echolucent plaques have been shown to
be more dangerous than echogenic plaques.30 El
Barghouty et al30 also noted that, in addition to the
echolucency of the plaque, the mean degree of steno-
sis associated with silent brain infarctions was signifi-
cantly higher (73% vs 61%; P < .01). Although we
note the B-mode plaque characteristics on our exam-
inations, we have not been able to predict which
plaques will progress based on the B-mode alone.
Perhaps in the future, better patient selection for
CEAs can be achieved by means of a combination of
plaque analysis and flow characteristics.
In summary, patients who are asymptomatic with
moderate stenosis are at significant risk for new neu-
rologic events and death. We found flow character-
istics facilitate the selection of patients who are like-
ly to have disease progression and suggest that they
should be examined on a semiannual basis with
duplex scans. 
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Dr Robert W. Hobson II (Newark, NJ). I would like
to thank the Society and its Program Committee for the
privilege of reviewing respected colleagues’ work, because
I consider it an honor and an obligation to this member-
ship. 
When I received the Program Committee’s letter
inviting me to discuss this paper, I was intrigued by the
authors’ abstract and its conclusions. Perhaps the Loyola
group had accomplished its goals: identification of a high-
risk subset of asymptomatic patients with stenoses of 50%
to 79%, and furthermore, a group that could be charac-
terized by means of flow characteristics on duplex ultra-
sonography that would assist us in better selection of
asymptomatic patients for carotid endarterectomy. 
However, after reviewing an abstract that describes
132 neurologic end points, a first manuscript received six
days ago that included 51 neurologic end points, and a
second manuscript received 2 days ago that included 75
neurologic end points, I must reluctantly conclude that
the Loyola group has been unable to fulfill the promise of
its originally submitted abstract. 
Let us first review some data about the identification of
a high-risk subset of asymptomatic patients. I chose to review
natural history data from the medical treatment arms of the
clinical trials, Asymptomatic Carotid Atherosclerosis Study
(ACAS) and Veterans Administration (VA). The annual ipsi-
lateral stroke rate for ACAS was 2.3%, for the VA trial was
2.4%, and for the Loyola cohort of patients was 2.1%, a risk
comparable with that previously described in the trials. 
However, in the second manuscript, the authors
added 20 contralateral strokes to the original report of 14
ipsilateral strokes. Perhaps, Dr Mansour, you can give us
DISCUSSION
some explanation about the cause of this relatively high
incidence of contralateral strokes. Although not reported
in your manuscript, the combined annual stroke risk, that
is, ipsilateral plus contralateral, in ACAS was 3.5% and in
the VA trial was 3%. What was your cohort’s combined
ipsilateral and contralateral stroke rate? 
Also, because you report such a large number of con-
tralateral strokes, can you give us some data on the inci-
dence of neurologic events in patients with unilateral 50%
to 79% stenosis, as opposed to those with bilateral disease?
What were the stroke severity scores of these described
end points? Was severity increased in this cohort, as com-
pared with previously published data? Do you think that
the age of patients studied may have had any influence on
your results? Mean age for the ACAS was 67 years, for the
VA trial was 64.5 years, and for this cohort of patients was
nearly 71 years. 
Finally, the authors’ goal of having flow characteristics
on duplex ultrasonography assist in identifying a high-risk
group of patients was not achieved. Although the second
manuscript suggests that their noninvasive laboratory data
did correlate with subsequent plaque progression, a care-
ful review of the manuscript shows that progression did
not, however, predict a higher neurologic event rate in this
asymptomatic population. Increasing my disappointment
about the noninvasive laboratory is the authors’ further
admonition that plaque morphology could not predict the
asymptomatic patient at higher risk. I would ask the
authors if they foresee any combination of laboratory test-
ing that might lead us to identification of this group? 
The goal of identifying a high-risk asymptomatic
cohort of patients with 50% to 79% stenosis continues to
be a meritorious one. In this era of cost-containment, it
may be difficult for us to continue to justify the perfor-
mance of 18 to 20 carotid endarterectomies to prevent
one stroke. Therefore, I commend the authors for their
effort and challenge all of us to search for this yet-to-be-
defined, elusive group of high-risk patients. 
Thank you for the opportunity to discuss this paper. 
Dr M. Ashraf Mansour. Thank you, Dr Hobson. I
must confess that I erred in sending you the first draft of
the manuscript with only ipsilateral strokes included. It is
more reasonable to evaluate the patients’ neurologic out-
come by studying what happens to them neurologically,
whether it was ipsilateral or contralateral stroke. Because
we are studying the patients and not the vessels, we should
report on their neurologic outcomes, as we did in the final
manuscript. 
The explanation for the higher incidence of contralat-
eral strokes is that there was a significant number of
patients, I believe 12 of the 20, who had contralateral
internal carotid artery occlusion. The incidence of stroke
associated with an occlusion can be quite significant; the
yearly stroke range is somewhere between 2% and 5%. 
I did not evaluate or could not find any information in
the charts on the stroke severity and the classification or
the classes of strokes on these patients. The diagnosis of
stroke was made by clinicians, neurologists, or other physi-
cians, or by means of a magnetic resonance imaging or
computed tomography scan of the brain that proved there
was an ischemic stroke on the side reported. 
I do agree with you that our patients were somewhat
older than those reported in the other studies and natural
history studies. Our patients averaged 70 years and older.
We had quite a few patients who were older than 80 years. 
Regarding the dilemma of how a duplex scan helps in
identifying patients who will either have disease progres-
sion or neurologic events: We could identify the patients
that would have disease progression by means of flow
characteristics. We could not identify who was going to
have neurologic events by means of any flow characteris-
tics. Dr Nicolaides presented some data in 1996 in the
European Journal of Vascular Surgery describing plaque
characteristics. His conclusion was that an echolucent
plaque had a higher risk than an echogenic plaque. He
combined that finding with the flow characteristics and
found that if there was an echolucent plaque and a higher
grade of stenosis these patients were at a higher risk for
silent infarcts or neurologic symptoms. 
Dr Thomas F. Panetta (Brooklyn, NY). My question
relates to your vascular laboratory diagnosis of carotid
stenosis. Your range for moderate stenosis was peak sys-
tolic velocities of 125 cm/s, ranging to end diastolic
velocities of 140 cm/s. In our laboratory, a peak systolic
velocity of 125 cm/s denotes a 40% to 59% lesion. Did
you stratify your moderate lesions, for example, with end
diastolic velocities of 80 to 140 cm/s or from 100 to 140
cm/s and look at that subset to see whether that group
was at increased risk for ipsilateral neurologic events? 
Dr Mansour. Thank you for your question. When we
started this study, our goal was to try to find a subset of
patients in that large 50%-to-79%-stenosis group who
were more at risk for disease progression or neurologic
symptoms. Our gut feeling was that the patients who had
more than 60% stenosis were more at risk of progressing.
And although the 60% cutoff was reported by Dr Moneta
as being 260 cm/s for peak systolic velocity and 70 cm/s
for end diastolic velocity, when we used those criteria on
our patients we could not predict the patients who would
end up having symptoms. So 60% is not a good cutoff
point for determining who is going to have a stroke.
However, the velocities that I showed you, 251 cm/s for
peak systolic velocity and 70 cm/s for end diastolic veloc-
ity, were predictive of patients who would end up with dis-
ease progression. 
Dr Richard W. Bock (Asheville, NC). In 1993 at these
meetings, we presented data from 242 asymptomatic
patients studied for years at the University of Sydney by
means of annual duplex. Our findings were nearly identical
to yours. Our contralateral event rate was more than dou-
ble the ipsilateral rate. I was unable to explain this effect. I
wonder if you’ve had better luck in analyzing why your
patients have more contralateral than ipsilateral events.
Dr Mansour. I haven’t been able to identify the specif-
ic reasons why the patients had a higher incidence of con-
tralateral strokes. Currently, we are trying to start a project
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examining cerebral blood flow and reserve that might
explain this; however, we haven’t started it yet. But, other
than your comments and some reports in the literature
discussing this, I have no good explanation for it. 
Dr Norman R. Hertzer (Cleveland, Ohio). The thing
that drew my attention to this abstract was the considerable
additional information in the literature to suggest that 60%
or 50% to 79% stenosis is not particularly dangerous, and we
can follow it in outpatients and recommend an operation
only if they creep into the 80% to 99% range. Now, I didn’t
get this from your presentation, but if we look only at ipsi-
lateral strokes, what is the stroke risk in your group for those
patients who remained in the 50% to 79% range, compared
with those who crept into the 80% to 99% range? Is 50% to
79% stenosis dangerous, or is it only if it progresses? 
Dr Mansour. It’s dangerous only if it progresses. The
ipsilateral stroke rate for patients with 50% to 79% stenoses
was 2.1% in our group.
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